This exclusive new report examines how Belgium has been able to establish itself as the ‘Pharma Valley of Europe’, famed for the quality and breadth of its medical research, the scale and complexity of its manufacturing infrastructure, and its multilingual, highly skilled, and industry savvy talent pool. It also looks at the wide variety of pharma multinationals who have chosen to situate regional headquarters, strategic hubs, as well as R&D and manufacturing sites in the country.

Other topics covered include how the country’s domestic market has evolved since the 2015 ‘Pact for the Future’ between industry and government, the impact of wide-ranging hospital network reforms, the continuing issue of low generics penetration, and much more.